Although EGFR inhibitor, an effective therapy for EGFR driven lung cancer, has been shown to down-modulate PD-L1 on lung cancer cell lines in our study and other reports [20,21], whether it leads to better T cell mediated tumor killing has not been clearly demonstrated. Here, EGFR is linked to lung carcinoma.